FDA approves Imaavy as first treatment specifically indicated for warm autoimmune haemolytic anaemia
- nuaxia
- 3 hours ago
- 2 min read
The approval extends Johnson & Johnson’s FcRn-blocking therapy into wAIHA, providing a new targeted treatment for adults with a rare autoimmune blood disorder that can cause severe and persistent haemolytic anaemia.
The US Food and Drug Administration (FDA) has approved Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA) in adults, making it the first FDA-approved therapy specifically indicated for the condition.
The approval is supported by the Phase III ENERGY study, in which Imaavy plus standard of care produced a higher rate of durable haemoglobin response than placebo plus standard of care.
Field | Content |
Alert Type | Drug Approval |
Drug Name | Imaavy (nipocalimab-aahu) |
Indication | Treatment of warm autoimmune haemolytic anaemia (wAIHA) in adults. |
Therapy Area(s) | Haematology; Autoimmune disease; Rare disease |
Geography | United States (FDA) |
What Happened | On 24 August 2026, the FDA approved Johnson & Johnson’s Imaavy (nipocalimab-aahu) for adults with wAIHA. Imaavy is a neonatal Fc receptor (FcRn)-blocking monoclonal antibody designed to reduce circulating IgG antibodies, including the pathogenic IgG autoantibodies responsible for red blood cell destruction in wAIHA. The approval makes Imaavy the first treatment specifically approved by the FDA for wAIHA and expands the drug’s US label beyond its existing indication in generalised myasthenia gravis. |
Why It Matters | wAIHA is a rare autoimmune disorder in which IgG autoantibodies target and destroy red blood cells, potentially resulting in severe anaemia, fatigue, breathlessness and other complications. Treatment has historically relied on approaches including corticosteroids and other immunosuppressive therapies rather than an FDA-approved medicine specifically indicated for wAIHA, so Imaavy introduces a targeted FcRn-directed treatment into the US pathway. |
Supporting Context | Approval was supported by the Phase III ENERGY study, which compared Imaavy plus standard of care with placebo plus standard of care in adults with wAIHA. The study met its primary endpoint, demonstrating a statistically significant improvement in durable haemoglobin response with Imaavy; the regulatory decision therefore establishes a new approved use for nipocalimab rather than a designation or preliminary recommendation. |
Key Takeaway | FDA approval of Imaavy introduces the first therapy specifically indicated for adults with wAIHA and establishes FcRn blockade as a new targeted treatment approach for the rare autoimmune blood disorder. |
What to Watch | Uptake of Imaavy within the wAIHA treatment pathway, particularly how clinicians position FcRn blockade relative to corticosteroids and other existing treatment approaches, as well as subsequent regulatory decisions for nipocalimab in additional autoimmune indications. |
Primary Source | |
Relevant Date | 24 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments